Back to Search Start Over

Stem cells and vascular regenerative medicine: A mini review.

Authors :
Stoltz, J.-F.
Bensoussan, D.
De Isla, N.
Zhang, L.
Han, Z.
Magdalou, J.
Huselstein, C.
Ye, J. S.
Leballe, B.
Decot, V.
Reppel, L.
Source :
Clinical Hemorheology & Microcirculation; 2016, Vol. 64 Issue 4, p613-633, 21p
Publication Year :
2016

Abstract

Most human tissues do not regenerate spontaneously, which is why "cell therapy" are promising alternative treatments. The Principe is simple: patients' or donors' cells are collected and introduced into the injured tissues or organs directly or in a porous 3D material, with or without modification of their properties. This concept of regenerative medicine is an emerging field which can be defined as "the way to improve health and quality of life by restoring, maintaining, or enhancing tissue and organ functions". There is an extraordinarily wide range of opportunities for clinical applications: artheropathies, diabetes, cartilage defects, bone repair, burns, livers or bladder regeneration, organs reconstruction (lung, heart, liver . . . ) neurodegenerative disorders, sepsis . . . Different stem cells (SC) with different potential can be used and characterised (totipotent, mesenchymal of different origins, especially those present in tissues. . . ). Today it is undeniable that cells like bone marrow, adipose tissue or Wharton Jelly stem cells, are of potential interest for clinical applications because they are easily separated and prepared and no ethical problems are involved in their use. In this paper some potential clinical applications in the vascular field are considered: peripheral arteriopathy in diabetic patients, cardiac insufficiency, traitment of erectile dysfunction, or organ regeneration with liver as example. But the regeneration of tissue or organ is and will remain a challenge for the future development of cell therapy. Many problems remain to be solved that could lead to the development of innovative strategies to facilitate cell differentiation, increase the yield of cells and ensure a standardised product, overcome the risks of teratogenic effects and/or immune reactions, enable grafting via direct cell or biotissue transplantation and avoid legal issues involved in national regulations. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13860291
Volume :
64
Issue :
4
Database :
Complementary Index
Journal :
Clinical Hemorheology & Microcirculation
Publication Type :
Academic Journal
Accession number :
121152439
Full Text :
https://doi.org/10.3233/CH-168036